MINIVELLE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for MINIVELLE (MINIVELLE).
Estradiol binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and regulation of target tissues including reproductive, cardiovascular, skeletal, and CNS systems.
| Metabolism | Primarily hepatic metabolism via CYP3A4 to estrone and estriol, followed by conjugation (glucuronidation, sulfation). |
| Excretion | Renal: 80-90% as glucuronide and sulfate conjugates; Fecal: 10-20% via bile; <1% unchanged. |
| Half-life | Terminal half-life: 12-18 hours for estradiol; clinical context: once-daily or twice-weekly dosing maintains steady-state concentrations. |
| Protein binding | 98% bound primarily to sex hormone-binding globulin (SHBG) and albumin. |
| Volume of Distribution | Approximately 1.2-1.5 L/kg; extensive distribution into tissues. |
| Bioavailability | Transdermal: approximately 82% of dose absorbed (avoid first-pass metabolism); oral: <5% due to extensive hepatic first-pass. |
| Onset of Action | Transdermal: detectable plasma levels within 1-2 hours; clinical effect (e.g., symptom relief) within 1-2 weeks. |
| Duration of Action | Transdermal: sustained release over 3-7 days depending on patch wear time; clinical effect persists as long as patch is applied. |
| Molecular Weight | 272.38 |
Transdermal: Apply 0.025-0.1 mg/day patch twice weekly (every 3-4 days).
| Dosage form | FILM, EXTENDED RELEASE |
| Renal impairment | No specific dosage adjustment recommended; use with caution in severe impairment. |
| Liver impairment | Contraindicated in severe hepatic disease (Child-Pugh class C). In mild to moderate impairment (Child-Pugh A or B), use lowest effective dose. |
| Pediatric use | Safety and efficacy not established; not FDA-approved for pediatric use. |
| Geriatric use | Use lowest effective dose; monitor for thromboembolic events and malignancy; consider shorter duration. |
| 1st trimester | Estrogens are contraindicated in pregnancy. There is no indication for use in the first trimester. Available data suggest increased risk of congenital anomalies, including cardiovascular and limb defects, with in utero estrogen exposure. |
| 2nd trimester | Estrogens are contraindicated in pregnancy. Use in second trimester should be avoided due to potential adverse effects on the fetus, including genitourinary tract abnormalities and possible carcinogenic effects. |
| 3rd trimester | Estrogens are contraindicated in pregnancy. Use in third trimester may cause urogenital abnormalities in the fetus and has been associated with an increased risk of endometrial cancer in daughters exposed in utero. |
Clinical note
Comprehensive clinical and safety monograph for MINIVELLE (MINIVELLE).
| Placental transfer | Estrogens, including estradiol, cross the placenta readily based on rodent studies and human data. Fetal serum concentrations can reach significant levels, especially with higher maternal doses. |
| Breastfeeding |
■ FDA Black Box Warning
Estrogens increase the risk of endometrial cancer in women with an intact uterus. Use progestin when uterus is present. Do not use for prevention of cardiovascular disease or dementia. Increased risk of probable dementia in women ≥65 years. Increased risk of breast cancer, stroke, DVT, and pulmonary embolism.
| Serious Effects |
Undiagnosed abnormal genital bleedingKnown or suspected pregnancyKnown or suspected breast cancerKnown or suspected estrogen-dependent neoplasiaActive or history of venous thromboembolism (e.g., deep vein thrombosis, pulmonary embolism)Active or history of arterial thromboembolism (e.g., stroke, myocardial infarction)Known thrombophilic disorders (e.g., factor V Leiden, antithrombin deficiency)Known liver disease or impaired liver functionHypersensitivity to estradiol or any component of the formulation
| Precautions | Cardiovascular disorders (stroke, MI, DVT), malignant neoplasms (endometrial, breast, ovarian), dementia, gallbladder disease, hypercalcemia, visual abnormalities, hereditary angioedema, exacerbation of endometriosis, and fluid retention. Minimize dose and duration. |
| Food/Dietary |
Loading safety data…
| Estrogens are excreted in human breast milk in small amounts. There are no adequate and well-controlled studies in nursing women. Use during breastfeeding may reduce milk production and composition; thus, it is generally not recommended. If used, monitor the infant for any adverse effects. |
| Lactation Rating | L3 (Moderately Safe) - Limited data suggest minimal risk; however, caution is advised due to potential effects on lactation. |
| Teratogenic Risk | Estrogens, including estradiol (MINIVELLE), are contraindicated in pregnancy. First trimester exposure is associated with a risk of congenital anomalies, particularly cardiovascular and urogenital defects. Second and third trimester exposure may increase risk of fetal reproductive tract abnormalities, including vaginal adenosis and clear cell adenocarcinoma in female offspring. Estrogens should not be used during pregnancy. |
| Fetal Monitoring | Monitor blood pressure, uterine growth, and fetal heart rate if inadvertently used during pregnancy. In cases of accidental exposure, assess for signs of fetal distress. Monitor for maternal adverse effects such as thromboembolism and hypertension. |
| Fertility Effects | Estrogens suppress gonadotropin secretion, potentially inhibiting ovulation and reducing fertility. Reversible upon discontinuation. Use as contraception is not indicated due to thrombotic risks. |
| Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism and increase estradiol levels. St. John's wort may induce estrogen metabolism and reduce efficacy. No significant interactions with other foods. |
| Clinical Pearls | Minivelle (estradiol transdermal system) delivers continuous estradiol for hormone therapy. Apply to clean, dry, intact skin on lower abdomen or upper buttock; avoid breasts and waistline. Rotate application sites with at least 1-week interval. Do not apply to oily, irritated, or sunburned skin. If patch falls off, reapply or replace with a new patch; maintain same schedule. Monitor for signs of thromboembolism, stroke, or breast cancer. Discontinue if migraine develops. Use lowest effective dose for shortest duration. |
| Patient Advice | Apply patch once weekly on the same day. · Choose a clean, dry area on your lower belly or upper buttock; never place on breasts. · Rotate application sites; do not use the same spot twice within 1 week. · If patch falls off, reapply a new one; if it has been off for more than 8 hours, apply a new patch and note the day. · Do not expose patch to direct heat sources (heating pads, saunas, sunbathing) as it may increase drug absorption. · Report any sudden severe headache, vision changes, chest pain, shortness of breath, or leg swelling/pain. · Avoid grapefruit juice and St. John's wort, as they may alter drug effectiveness. · Do not smoke while using this medication; smoking increases risk of blood clots and heart disease. |